233 related articles for article (PubMed ID: 29023959)
1. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?
Rammohan A; Reddy MS; Farouk M; Vargese J; Rela M
Hepatology; 2018 Mar; 67(3):1166-1168. PubMed ID: 29023959
[No Abstract] [Full Text] [Related]
2. Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma.
Varkaris A; Lewis DW; Nugent FW
Am J Gastroenterol; 2017 Dec; 112(12):1895-1896. PubMed ID: 29215617
[No Abstract] [Full Text] [Related]
3. A novel immunosuppression-based classification of liver tumors opens new perspectives for adapted therapeutic strategies.
Bévant K; Coulouarn C
EBioMedicine; 2020 Apr; 54():102737. PubMed ID: 32268278
[No Abstract] [Full Text] [Related]
4. Joining the dots for better liver cancer treatment.
Chan LK; Ng IO
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):74-75. PubMed ID: 31712772
[No Abstract] [Full Text] [Related]
5. Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report.
Wu Z; Lai L; Li M; Zhang L; Zhang W
Medicine (Baltimore); 2017 Dec; 96(51):e9431. PubMed ID: 29390572
[TBL] [Abstract][Full Text] [Related]
6. Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma.
Stauner CT; Drexler K; Berneburg M; Haferkamp S
J Dtsch Dermatol Ges; 2018 Nov; 16(11):1376-1378. PubMed ID: 30299577
[No Abstract] [Full Text] [Related]
7. [A long-term survival case of hepatocellular carcinoma recurrence after the patient received a living donor liver transplantation treated by combined modality therapy].
Hama N; Marubashi S; Dono K; Kobayashi S; Kim C; Asaoka T; Takeda Y; Nagano H; Umeshita K; Monden M; Doki Y; Mori M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2092-5. PubMed ID: 19106534
[TBL] [Abstract][Full Text] [Related]
8. Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure.
Schulte N; Li M; Zhan T; Dreikhausen L; Sollors J; Antoni C; Diehl S; Schoenberg SO; Rahbari N; Reissfelder C; Giordano FA; Ebert MP; Teufel A
Z Gastroenterol; 2020 Aug; 58(8):773-777. PubMed ID: 32785913
[TBL] [Abstract][Full Text] [Related]
9. Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.
Zhang Z; Zhou Y; Hu K; Li Z; Wang Z; Huang Y
Dig Liver Dis; 2019 Oct; 51(10):1488-1490. PubMed ID: 31401020
[No Abstract] [Full Text] [Related]
10. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
[No Abstract] [Full Text] [Related]
11. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait.
Rizzo A; Ricci AD; Brandi G
Immunotherapy; 2021 Jun; 13(8):637-644. PubMed ID: 33820447
[TBL] [Abstract][Full Text] [Related]
12. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature.
Wilde L; Ali SM; Solomides CC; Ross JS; Trabulsi E; Hoffman-Censits J
Clin Genitourin Cancer; 2017 Jun; 15(3):e521-e524. PubMed ID: 28143711
[No Abstract] [Full Text] [Related]
13. Determining the Efficacy of Pembrolizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma.
Lin TA; Das A; McCaw Z; Ludmir EB
J Clin Oncol; 2023 Jun; 41(16):3074-3075. PubMed ID: 37015029
[No Abstract] [Full Text] [Related]
14. Chronic myeloid leukemia after living donor liver transplantation.
Concejero A; Chen CL; Wang CC; Wang SH; Lin CC; Liu YW; Yang CH; Yong CC; Wang MC; Eng HL
Transplantation; 2007 Jun; 83(11):1521-2. PubMed ID: 17565329
[No Abstract] [Full Text] [Related]
15. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.
Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M
Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070
[TBL] [Abstract][Full Text] [Related]
16. Vasculitic neuropathy induced by pembrolizumab.
Aya F; Ruiz-Esquide V; Viladot M; Font C; Prieto-González S; Prat A; Arance A
Ann Oncol; 2017 Feb; 28(2):433-434. PubMed ID: 27864214
[No Abstract] [Full Text] [Related]
17. Shifting paradigms in the systemic management of hepatocellular carcinoma.
Pinato DJ
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):883-885. PubMed ID: 32941832
[No Abstract] [Full Text] [Related]
18. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
[TBL] [Abstract][Full Text] [Related]
19. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma.
Sun R; Moraleda JM; Wei LJ
JAMA Oncol; 2024 May; 10(5):674. PubMed ID: 38483380
[No Abstract] [Full Text] [Related]
20. Multifocal hepatocellular carcinoma in patients undergoing living-related liver transplantation.
Hirohashi K; Yamamoto T; Shuto T; Uenishi T; Ogawa M; Sakabe K; Tanaka S; Kanazawa A; Tanaka H; Kubo S; Kinoshita H
Hepatogastroenterology; 2003; 50(53):1617-20. PubMed ID: 14571798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
